Aliases:This biomarker is also known as:
- regulator of G-protein signalling 5,
- regulator of G-protein signaling 5,
RGS5 is a member of the regulators of G protein signaling (RGS) family, which are signal transduction molecules that are involved in the regulation of heterotrimeric G proteins by acting as GTPase activators. RGS5 has been found to be involved in tumor angiogenesis and to antagonize the angiogenic effect of VEGF. Multiple alternatively spliced transcript variants have been found.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
RGS5 has been found to be up-regulated in many types of malignant cells, including breast cancer.
RGS5 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- HGNC entry for RGS5 from Genenames
- KEGG entry for RGS5 from Genome.jp
- Entrez entry for RGS5 all NCBI Databasese
- Human GEO Profiles for RGS5 from NCBI GEO Profiles
- Human Geo Datasets containing term RGS5 from NCBI GEO Datasets
- GWAS Study Datasets containing gene RGS5 from GWAS
- Human Single Nucleotide Polymorphisms info for RGS5
- Human Gene(s) with 'RGS5' as Gene Name/Alias
- Human Gene RefSeq for RGS5 from NCBI
- GeneCards entry for human RGS5
- UniProtKB/Swiss-Prot entry for RGS5 from Uniprot
- Human Protein RefSeq for RGS5 from NCBI
- FDA web page describing approval of RGS5
|UniProt Accession #:||O15539|
|Mutated Sites Count:||62|
|Associated Pubmed ID Count||5|
|Affected Protein Function Sites Count:||4|